翰宇药业：预计2025年全年实现营业收入9.50亿元至9.80亿元，归母净利润实现扭亏为盈

Core Viewpoint - The company, Hanyu Pharmaceutical, anticipates a significant improvement in its financial performance for the year 2025, with projected revenues between 950 million and 980 million yuan and a return to profitability with net profits estimated between 40 million and 50 million yuan [1] Financial Performance - For the year 2025, the company expects to achieve operating revenue of 950 million to 980 million yuan [1] - The company forecasts a net profit of 40 million to 50 million yuan, indicating a turnaround from previous losses [1] Strategic Initiatives - In the second half of 2025, the company plans to increase its research and development investments, capacity building, and international expansion to capitalize on the rapid growth opportunities in the GLP-1 global market [1] - The related expenses for these strategic initiatives will be concentrated, but the company maintains a positive outlook on its core business and sufficient operating cash flow [1]